Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 150/37.5/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 175/43.75/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

European Union - English - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 50/12.5/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 75/18.75/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 100/25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 125/31.25/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - levodopa ; carbidopa ; entacapone - film coated tablet - 200/50/200 milligram - levodopa, decarboxylase inhibitor and comt inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: indigo carmine; hypromellose; hyprolose; allura red ac; magnesium stearate - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr in patients who have not been treated with levodopa before.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increased incidences of viscer